Jinju Chen

Jinju Chen

Auto-generated profile, based on publicly available information

Jinju Chen

Jing Medicine Technology (Shanghai) Ltd., 6th Floor, Y-building, 230 Haike Road, Shanghai, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2022 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
YDYong Du
Yong Du
YCYongfeng Chen
Yongfeng Chen
YWYuxia Wang
Yuxia Wang
JCJinju Chen
Jinju Chen
XLXiaorong Lu
Xiaorong Lu
GZGeorge Zhang
George Zhang
The EGFR C797S mutation is the most common on-target resistance mechanism to osimertinib in patients with advanced non–small cell lung cancer (NSCLC). Currently there are no effective treatment options for patients with NSCLC harboring EGFR C797S triple mutants (Del19/T790M/C797S and L858R/T790M/C797S). Herein, we report an orally bioavailable EGFR PROTAC, HJM-561, which selectively degrades the EGFR C797S-containing triple mutants. HJM-561 potently inhibits the proliferation of Del19/T790M/C797S and L858R/T790M/C797S Ba/F3 cells while sparing cells expressing wild-type EGFR. Oral administration of HJM-561 shows robust antitumor activity in EGFR Del19/T790M/C797S-driven Ba/F3 CDX and PDX models that were resistant to osimertinib treatment. Taken together, our results suggest that HJM-561 is a promising therapeutic option for overcoming EGFR triple mutation-mediated drug resistance in NSCLC. Watch the interview with George Zhang, PhD, recipient of the 2024 Molecular Cancer Therapeutics Award for Outstanding Journal Article: https://vimeo.com/992990122

3 April 2023
Verified
Other
Open access
YDYong Du
Yong Du
YCYongfeng Chen
Yongfeng Chen
YWYuxia Wang
Yuxia Wang
JCJinju Chen
Jinju Chen
XLXiaorong Lu
Xiaorong Lu
GZGeorge Zhang
George Zhang
Supplementary Data from HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations


3 April 2023
Verified
Other
Open access
YDYong Du
Yong Du
YCYongfeng Chen
Yongfeng Chen
YWYuxia Wang
Yuxia Wang
JCJinju Chen
Jinju Chen
XLXiaorong Lu
Xiaorong Lu
GZGeorge Zhang
George Zhang
The EGFR C797S mutation is the most common on-target resistance mechanism to osimertinib in patients with advanced non–small cell lung cancer (NSCLC). Currently there are no effective treatment options for patients with NSCLC harboring EGFR C797S triple mutants (Del19/T790M/C797S and L858R/T790M/C797S). Herein, we report an orally bioavailable EGFR PROTAC, HJM-561, which selectively degrades the EGFR C797S-containing triple mutants. HJM-561 potently inhibits the proliferation of Del19/T790M/C797S and L858R/T790M/C797S Ba/F3 cells while sparing cells expressing wild-type EGFR. Oral administration of HJM-561 shows robust antitumor activity in EGFR Del19/T790M/C797S-driven Ba/F3 CDX and PDX models that were resistant to osimertinib treatment. Taken together, our results suggest that HJM-561 is a promising therapeutic option for overcoming EGFR triple mutation-mediated drug resistance in NSCLC.

3 April 2023
Verified
Other
Open access
YDYong Du
Yong Du
YCYongfeng Chen
Yongfeng Chen
YWYuxia Wang
Yuxia Wang
JCJinju Chen
Jinju Chen
XLXiaorong Lu
Xiaorong Lu
GZGeorge Zhang
George Zhang
The EGFR C797S mutation is the most common on-target resistance mechanism to osimertinib in patients with advanced non–small cell lung cancer (NSCLC). Currently there are no effective treatment options for patients with NSCLC harboring EGFR C797S triple mutants (Del19/T790M/C797S and L858R/T790M/C797S). Herein, we report an orally bioavailable EGFR PROTAC, HJM-561, which selectively degrades the EGFR C797S-containing triple mutants. HJM-561 potently inhibits the proliferation of Del19/T790M/C797S and L858R/T790M/C797S Ba/F3 cells while sparing cells expressing wild-type EGFR. Oral administration of HJM-561 shows robust antitumor activity in EGFR Del19/T790M/C797S-driven Ba/F3 CDX and PDX models that were resistant to osimertinib treatment. Taken together, our results suggest that HJM-561 is a promising therapeutic option for overcoming EGFR triple mutation-mediated drug resistance in NSCLC.Watch the interview with George Zhang, PhD, recipient of the 2024 Molecular Cancer Therapeutics Award for Outstanding Journal Article: https://vimeo.com/992990122